Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus for recurrent implantation failure during frozen embryo transfer
IRCT20240429061583N1Phase 3Completed
- Sponsor
- ACECR
- Start
- Apr 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus in Recurrent Implantation Failure (RIF) (2 arms), sponsored by ACECR. Primary endpoints: Chemical pregnancy rate, Clinical pregnancy rate and 2 more. Started Apr 2024; status: completed.
02
Drugs
tacrolimus
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on IRCT20240429061583N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240429061583N1.